SS Innovations International Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console in a series of remote operations during October 2026 medical conferences in Spain and India. The highlight was a robotic-assisted atrial septal defect procedure performed by Dr. Sudhir Srivastava, the company's chairman and CEO, on a patient approximately 7,500 miles away in Bengaluru, India, during the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona.
The company also reported that four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric, and gynecological procedures. As of October 23, 2026, SS Innovations said 205 telesurgeries have been performed with the SSi Mantra system, including cardiac procedures. These demonstrations underscore the potential for remote robotic surgery to extend specialist expertise beyond major medical centers, which could improve access to advanced care in underserved regions. However, widespread adoption will depend on clinical validation, connectivity, and regulatory requirements.
For investors, the news is significant because SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA's review. FDA clearance would open the U.S. market, one of the largest for surgical robotics, and could accelerate adoption of the company's technology. The remote surgery demonstrations also position SS Innovations in the emerging field of telesurgery, where demand could grow as health systems seek to leverage specialist expertise across distances.
The company's progress is being tracked closely by investors and industry observers. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The announcements were disseminated through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides access to services including editorial syndication to 5,000+ outlets and social media distribution to millions of followers, helping companies like SS Innovations reach a broad audience of investors and journalists.
As robotic surgery evolves, the ability to perform complex procedures remotely could reshape how care is delivered, particularly for patients in areas lacking specialized surgeons. SS Innovations' demonstrations represent a step toward that future, though the company still faces the hurdle of regulatory clearance and the need for robust clinical evidence. For now, the telesurgery milestone and the pending FDA review are key developments to watch.
